Article
Oncology
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang
Summary: This study analyzed the outcomes of advanced EGFR-mutated non-small cell lung cancer patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs. The majority of resistance to first-line therapy was associated with the T790M mutation. Sequential osimertinib treatment in patients with positive secondary T790M mutation showed better outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ying-Yi Chen, Kuan-Hsun Lin, Yen-Shou Kuo, Yuan-Ming Tsai, Hsu-Kai Huang, Tsai-Wang Huang
Summary: This study investigated the impact of EGFR-TKI in patients with advanced lung adenocarcinoma treated with various therapeutic strategies. The results showed that TKI with lung cancer salvage surgery is the best therapeutic strategy, leading to significantly longer overall survival and extended duration of TKI usage.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
Summary: This study investigated 363 patients with advanced lung adenocarcinoma harboring EGFR mutations and evaluated the efficacy of afatinib, erlotinib, and gefitinib according to mutation type. E19del and L858R mutations were associated with superior progression-free survival and overall survival compared to uncommon mutations. Afatinib showed significantly longer progression-free survival across all EGFR mutation types.
Article
Medicine, General & Internal
Wei-Xiang Zhong, Xi-Feng Wei
Summary: In lung adenocarcinoma patients, co-mutations of EGFR and ALK genes are relatively common, especially in women, non-smokers, and patients with bone metastasis. These patients prefer EGFR-TKIs as their targeted therapy drugs, but the therapeutic effect is not satisfactory.
WORLD JOURNAL OF CLINICAL CASES
(2022)
Article
Chemistry, Multidisciplinary
Paolo Zucchiatti, Giovanni Birarda, Andrea Cerea, Marta S. Semrau, Aliaksandr Hubarevich, Paola Storici, Francesco De Angelis, Andrea Toma, Lisa Vaccari
Summary: This study demonstrates the potential of SEIRA microscopy in detecting subtle secondary structure modifications associated with the binding of Lapatinib to EGFR. By optimizing techniques and data analysis, the researchers successfully identified secondary structure modifications in EGFR related to a few amino acids.
Review
Oncology
Anita Brouns, Safiye Dursun, Gerben Bootsma, Anne-Marie C. Dingemans, Lizza Hendriks
Summary: Around 30-60% of lung cancer patients develop bone metastases, with those carrying an EGFR mutation being more prone to it. However, there is still a lack of research on bone metastases in clinical trials.
Article
Oncology
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu
Summary: This retrospective analysis compared the efficacy of afatinib combined with bevacizumab to erlotinib combined with bevacizumab in the first-line treatment of EGFR-mutated NSCLC, showing no significant difference in objective response rate and disease control rate between the two combination therapies, with diarrhea being more common in the afatinib group.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Clinical Neurology
Yu Wang, Jing Li, Tao Liu, Mengxi Ge, Xiaoyu Ji, Zhaohui Chu, Qiong Zhan, Xiaohua Liang, Xinli Zhou
Summary: This study investigated treatment strategies and clinical outcomes in patients with non-small-cell lung cancer (NSCLC) and leptomeningeal metastasis (LM). The findings showed that the use of third-generation tyrosine kinase inhibitors (TKIs) significantly improved LM progression-free survival (LMPFS) and overall survival (OS) in NSCLC patients with EGFR T790M mutation. Better Eastern Cooperative Oncology Group performance status, EGFR exon 19del, and clinical improvement of LM after therapy were independently associated with better OS.
WORLD NEUROSURGERY
(2023)
Article
Oncology
Qing Chang, Huiping Qiang, Jialin Qian, Yuqiong Lei, Jiahuan Lu, Hui Feng, Yiming Zhao, Baohui Han, Yanwei Zhang, Tianqing Chu
Summary: For advanced Chinese female lung SCC patients with EGFR positive mutations, targeted therapy could confer longer progression-free survival (PFS) and overall survival (OS) than chemotherapy, but the survival was similar with patients who were negative EGFR mutations.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cell Biology
Yukari Tsubata, Ryosuke Tanino, Takeshi Isobe
Summary: The discovery of EGFR mutations and the development of EGFR-TKIs have revolutionized the treatment of NSCLC. Despite the efficacy of EGFR-TKIs, resistance remains a major issue, driving the need for further research to improve prognosis in NSCLC.
Article
Oncology
Xuelin Zhang, Tengfei Ye, Mingdong Li, Hongwang Yan, Hui Lin, Hongsheng Lu, Zecheng Qi, Haihui Sheng, Chunya He
Summary: SNPs in inflammation genes were associated with the prognosis of NSCLC patients treated with EGFR-TKIs. Three SNPs were significantly associated with worse PFS, and five SNPs were significantly associated with worse OS. High and intermediate GRSs were associated with worse PFS, and high GRSs were associated with shorter survival time for OS. Furthermore, IL15, IL17RA, AGER, MIF, and TNFRSF1A were dysregulated in LUAD. There was a difference in the expression level of TNFRSF1A between EGFR wildtype and EGFR-mutant LUAD. Low AGER expression and high TNFRSF1A expression were significantly associated with worse PFS in LUAD. Additionally, low IL17RA and AGER expression, and high MIF and TNFRSF1A expression were significantly associated with worse OS in LUAD.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Keunchil Park, Pasi A. Janne, Dong-Wan Kim, Ji-Youn Han, Ming-Fang Wu, Jong-Seok Lee, Jin-Hyoung Kang, Dae Ho Lee, Byoung Chul Cho, Chong-Jen Yu, Yong Kek Pang, Enriqueta Felip, Hyunjin Kim, Eunhye Baek, Young Su Noh
Summary: Olmutinib demonstrates meaningful clinical activity and a manageable safety profile in patients with T790M-positive non-small cell lung cancer.
Article
Medicine, General & Internal
Yuman Yu, Yuehong Wang, Linying Wu, Xuanli Xu, Hua Zhou, Qing Wang, Jianying Zhou
Summary: The study evaluated the efficacy of EGFR-TKIs plus bevacizumab in advanced non-squamous EGFR-mutated NSCLC patients with gradual progression, showing that the treatment was well-tolerated and promising. Patients with high baseline serum VEGF levels had better PFS2 than those with low baseline levels.
Article
Oncology
E. Zhou, Feng Wu, Mengfei Guo, Zhengrong Yin, Yumei Li, Minglei Li, Hui Xia, Jingjing Deng, Guanghai Yang, Yang Jin
Summary: The established ERS in this study can predict a poor prognosis for LUAD patients and has the potential to predict drug responses.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R. Joseph, Fiona Simpson
Summary: This review critically analyzes the mechanisms of EGFR expression in NSCLC, its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC.